SANOFI-AVENTIS (EPA:SAN) | WebDisclosure

Basculer en Français

10639	Companies
226185	Keywords
154652	Articles
119691	Press releases

Home
Companies
SANOFI-AVENTIS

PRESS RELEASE

published on 05/31/2024 at 12:00, 2 years ago

Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan
Sanofi launches 2024 global Employee Stock Purchase Plan, Action 2024, offering discounted shares to 80,000 employees in 56 countries. CEO Paul Hudson affirms commitment to employee participation and company growth

Company Growth Sanofi Employee Stock Purchase Plan Action 2024 Employee Shareholders
PRESS RELEASE

published on 05/31/2024 at 12:00, 2 years ago

Communiqué de presse : Sanofi lance son plan mondial 2024 d’actionnariat salarié
Sanofi lance son plan mondial 2024 d'actionnariat salarié, ouvert à 80 000 salariés dans 56 pays, offrant actions à 72,87 € avec décote de 20%. Conditions et dates clés précisées pour la souscription

Actionnariat Salarié Souscription Sanofi Plan 2024 Entreprise De Santé
BRIEF

published on 05/31/2024 at 07:10, 2 years ago

Le CHMP recommande l'approbation de Dupixent dans l'UE pour le traitement des patients atteints de BPCO

Sanofi BPCO Dupixent CHMP Approvisionnement
BRIEF

published on 05/31/2024 at 07:10, 2 years ago

CHMP recommends approval of Dupixent in the EU for the treatment of patients with COPD

Sanofi COPD Dupixent CHMP Supply
PRESS RELEASE

published on 05/31/2024 at 07:05, 2 years ago

Communiqué de presse : Le CHMP recommande l'approbation de Dupixent dans l'UE pour le traitement des patients atteints de BPCO
Le CHMP recommande l'approbation de Dupixent dans l'UE pour le traitement des patients atteints de BPCO. Dupixent deviendrait la première thérapie ciblée pour la BPCO en Europe

Traitement Approbation BPCO Dupixent CHMP
PRESS RELEASE

published on 05/31/2024 at 07:05, 2 years ago

Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
European Medicines Agency's CHMP recommends Dupixent for EU approval to treat uncontrolled COPD with raised blood eosinophils. If approved, it would be the first targeted therapy for COPD in the EU

Dupixent CHMP EU Approval COPD Treatment Type 2 Inflammation
BRIEF

published on 05/30/2024 at 15:06, 2 years ago

Sanofi finalise l’acquisition d’Inhibrx, Inc.

Acquisition Sanofi Maladies Rares Inhibrx SAR447537
BRIEF

published on 05/30/2024 at 15:06, 2 years ago

Sanofi Completes Acquisition of Inhibrx, Inc.

Acquisition Sanofi Rare Diseases Inhibrx SAR447537
PRESS RELEASE

published on 05/30/2024 at 15:01, 2 years ago

Communiqué de presse : Sanofi finalise l’acquisition d’Inhibrx, Inc.
Sanofi finalise l’acquisition d’Inhibrx, Inc. ajoutant le SAR447537 à son portefeuille pour le développement de médicaments différenciés dans les maladies rares

Acquisition Sanofi Maladies Rares Inhibrx SAR447537
PRESS RELEASE

published on 05/30/2024 at 15:01, 2 years ago

Press Release: Sanofi completes acquisition of Inhibrx, Inc.
Sanofi completes acquisition of Inhibrx, Inc., adding SAR447537 to rare disease pipeline. Former Inhibrx shareholders receive $30.00 per share in cash and one contingent value right. Inhibrx Biosciences begins trading on NASDAQ as INXB

Acquisition Nasdaq Sanofi Inhibrx SAR447537

Accesswire

Published on 06/25/2026 at 14:01, 16 minutes ago

Worksport (NASDAQ:WKSP) Regains $1 Bid Price Requirement, Announces CEO Town Hall, Highlights Multiple Recent Growth Drivers in CEO Letter
Published on 06/25/2026 at 14:00, 17 minutes ago

Horizon Aircraft's Leadership Team to Participate at Farnborough International Airshow 2026
Published on 06/25/2026 at 13:50, 27 minutes ago

CoTec Holdings Corp. Announces Annual and Special Meeting Results
Published on 06/25/2026 at 13:45, 32 minutes ago

Amarc And Boliden Commence a $4 Million Exploration Program at the Duke District, BC
Published on 06/25/2026 at 13:30, 47 minutes ago

Nextech3D.ai Reports Strong Q4 and Audited Full-Year Results +216% YoY Q4 Revenue Growth, 91% Gross Margins, +106% Sequential Revenue Growth

View all ACCESSWIRE

EQS Group

Published on 06/25/2026 at 13:39, 38 minutes ago

EQS-Adhoc: Sirma Group Holding JSC: Transactions in Own Shares under the Share Buyback Program
Published on 06/25/2026 at 13:30, 47 minutes ago

MCH Group and Jupiter Festival Miami Enter Into Strategic Partnership
Published on 06/25/2026 at 13:20, 57 minutes ago

SBB Passenger Transport relies on IVU.cloud
Published on 06/25/2026 at 13:00, 1 hour 17 minutes ago

Pylontech Unveils PyOcean, a 6.4MWh Energy Storage System Powered by Self-Developed 601Ah Cells
Published on 06/25/2026 at 12:50, 1 hour 27 minutes ago

MindMaze Therapeutics Announces Results of Annual General Meeting

Les Echos

Published on 06/25/2026 at 07:30, 6 hours 47 minutes ago

Gimv signs an agreement to acquire Groupe Cap Vert, France’s leading multi-specialist provider of tree and vegetation critical management services, from Ambienta.
Published on 06/25/2026 at 07:30, 6 hours 47 minutes ago

Gimv ondertekent een overeenkomst voor de overname van Groupe Cap Vert, de Franse marktleider in multispecialistische essentiële diensten voor het beheer van bomen en groene infrastructuur, van Ambienta.
Published on 06/25/2026 at 07:30, 6 hours 47 minutes ago

Gimv signe un accord en vue d’acquérir le Groupe Cap Vert, leader français multi-spécialiste des services de gestion du patrimoine arboré et végétal, auprès d’Ambienta
Published on 06/24/2026 at 19:00, 19 hours 17 minutes ago

ALTAREA - Succès de l’option pour le paiement du dividende en actions : taux de souscription de 78,5 %
Published on 06/24/2026 at 18:00, 20 hours 17 minutes ago

Annual Results 2025-26

View all LES ECHOS COMFI WIRE